Cargando…

Neutralization and Stability of SARS-CoV-2 Omicron Variant

The SARS-CoV-2 B.1.1.529/Omicron variant was first characterized in South Africa and was swiftly designated a variant of concern(1). Of great concern is its high number of mutations, including 30–40 mutations in the virus spike (S) protein compared to 7–10 for other variants. Some of these mutations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Cong, Evans, John P., Qu, Panke, Faraone, Julia, Zheng, Yi-Min, Carlin, Claire, Bednash, Joseph S., Zhou, Tongqing, Lozanski, Gerard, Mallampalli, Rama, Saif, Linda J., Oltz, Eugene M., Mohler, Peter, Xu, Kai, Gumina, Richard J., Liu, Shan-Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722590/ https://www.ncbi.nlm.nih.gov/pubmed/34981053 http://dx.doi.org/10.1101/2021.12.16.472934

Ejemplares similares

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
por: Evans, John P., et al.
Publicado: (2022)

Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
por: Faraone, Julia N., et al.
Publicado: (2023)

Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants
por: Qu, Panke, et al.
Publicado: (2022)

Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
por: Qu, Panke, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H
por: Zeng, Cong, et al.
Publicado: (2021)

Erratum for Zeng et al., “Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H”
por: Zeng, Cong, et al.
Publicado: (2021)

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2022)

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2023)

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
por: Evans, John P., et al.
Publicado: (2022)

Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection
por: Evans, John P., et al.
Publicado: (2021)

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
por: Qu, Panke, et al.
Publicado: (2023)

Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
por: Qu, Panke, et al.
Publicado: (2023)

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
por: Qu, Panke, et al.
Publicado: (2022)

Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
por: Qu, Panke, et al.
Publicado: (2022)

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors
por: Zeng, Cong, et al.
Publicado: (2020)

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
por: Faraone, Julia N., et al.
Publicado: (2023)

Impaired Neutralizing Antibody Response to COVID-19 mRNA Vaccines in Cancer Patients
por: Zeng, Cong, et al.
Publicado: (2021)

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
por: Zeng, Cong, et al.
Publicado: (2021)

Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants
por: Qu, Panke, et al.
Publicado: (2023)

Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation
por: Lendermon, Elizabeth A., et al.
Publicado: (2017)

Neutralization susceptibility of Omicron lineages
por: Minton, Kirsty
Publicado: (2022)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
por: Wang, Xue-Jun, et al.
Publicado: (2022)

SARS-CoV-2 Spreads through Cell-to-Cell Transmission
por: Zeng, Cong, et al.
Publicado: (2021)

SARS-CoV-2 spreads through cell-to-cell transmission
por: Zeng, Cong, et al.
Publicado: (2021)

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer
por: Zeng, Cong, et al.
Publicado: (2022)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
por: Peng, Weiyu, et al.
Publicado: (2023)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Delta-Omicron recombinant escapes therapeutic antibody neutralization
por: Duerr, Ralf, et al.
Publicado: (2023)

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
por: Zou, Jing, et al.
Publicado: (2022)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023)

Post-Vaccination Neutralization Responses to Omicron Sub-Variants
por: Jacobsen, Henning, et al.
Publicado: (2022)

Neutralization, effector function and immune imprinting of Omicron variants
por: Addetia, Amin, et al.
Publicado: (2023)

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
por: Doria-Rose, Nicole A., et al.
Publicado: (2021)

Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2
por: Bednash, Joseph S., et al.
Publicado: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ugva0fpraj4diams0pjr2e9lc